How Investors May Respond To Immunovant (IMVT) After Sjögren’s Trial Failure

• Immunovant has come under pressure after Argenx reported a late stage failure in a Sjögren’s disease trial, raising fresh questions about the underlying approach for autoimmune therapies targeting this condition, including Immunovant’s mid stage IMVT-1402 program and its broader development priorities.
• The setback follows Immunovant’s recent decision to discontinue a cutaneous lupus program after missing its main goal, which puts more weight on execution risk, trial design quality and indication selection across the remaining IMVT-1402 pipeline, particularly in Sjögren’s disease.
• We will examine how Immunovant's investment narrative holds up as Argenx's failed Sjögren’s trial increases scrutiny on FcRn autoimmune programs.

Broaden your watchlist beyond Immunovant by scanning a curated 31 resilient stocks with low risk scores to help balance the kind of trial and execution risk highlighted by this latest autoimmune setback.

Immunovant Investment Narrative Recap

For an investor to stay in Immunovant, the core belief is that FcRn inhibition with IMVT-1402 can translate into real autoimmune therapies across several indications. The recent Argenx setback in Sjögren’s disease increases scientific doubt around that thesis but does not directly change Immunovant’s ongoing trial designs or timelines yet.

The key near term catalyst still sits with IMVT-1402 clinical readouts, especially in difficult to treat rheumatoid arthritis and Graves’ disease. The biggest current risk is that any underwhelming efficacy or safety signal, or delay across these programs, could extend Immunovant’s pre revenue status and reopen questions about future funding and dilution.

The cutaneous lupus program discontinuation is the most relevant recent announcement for this situation. Management stopped development after that study missed its main goal, which puts more focus on how Immunovant selects and prioritises indications for IMVT-1402, including Sjögren’s disease, where Argenx just reported its trial failure.

This move concentrates operational effort on the larger potential drivers, such as D2T rheumatoid arthritis and Graves’ disease. However, it also tightens the margin for error around upcoming data. For you as a shareholder, the cutaneous lupus decision and the Sjögren’s overhang both feed into the same question: can Immunovant execute cleanly enough on the remaining trials to justify its current R&D spend and future valuation expectations?

Immunovant's current analyst narrative points to forecast revenue of US$559.3 million and projected earnings of US$101.9 million by 2029, off a base of no revenue and a current loss of US$538.2 million in earnings today. This implies an earnings increase of about US$640 million if that consensus proves accurate.

Uncover why Immunovant's fair value indicates a 58% potential upside to its current price, a gap that could close more quickly than many investors expect.

Exploring Other Perspectives

One alternate lens for Immunovant focuses on trial scale and timing risk. The most cautious analysts assume revenue of only US$1.4 million and earnings of about US$206.6 thousand by 2029, which is far below the consensus figures. That gap shows how sharply views could shift as the Sjögren’s setback filters into future forecasts.

Explore another Immunovant fair value estimate, including one that suggests it could be worth just $48.07!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own independent judgment.

• A great starting point for your Immunovant research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• See our latest analysis for Immunovant. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Immunovant's overall financial health at a glance.

Looking for more investment ideas beyond Immunovant?

Once you have formed a view on Immunovant, it can help to cross check that conviction against a wider watchlist. The Simply Wall St screener lets you quickly filter for different types of opportunities so you can balance higher trial risk names with steadier holdings.

• For investors who want income to play a bigger role in portfolio returns, consider screening for companies with resilient payouts using 8 dividend fortresses.
• If capital preservation and balance sheet strength matter most, you can narrow the field to businesses with robust finances through a targeted list of solid balance sheet and fundamentals (25 results).
• Those hunting for less crowded opportunities can focus on quality businesses that are not yet widely followed by using a curated 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com